Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
23 results
  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

25-110          Phase I

3263-001: A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

  • Sarcoma, Pancreatic Cancer, Thyroid Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Colorectal Cancer, Sarcoma, Prostate Cancer, Pancreatic Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer

25-464          Phase I

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors

  • Gastric (Stomach) Cancer, Esophageal Cancer, Pancreatic Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Bladder Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Colorectal Cancer, Lung Cancer, Pancreatic Cancer

25-022          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

  • Colorectal Cancer, Lung Cancer, Pancreatic Cancer

25-812          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0511 in Participants with KRAS Mutated or Amplified Advanced Solid Tumors

  • Ovarian Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer, Bladder Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Lung Cancer, Melanoma

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Endometrial Cancer, Colorectal Cancer, Bladder Cancer

25-783          Phase I

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

25-375          Phase I

A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS PI3Ka inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Showing 1 - 10 of 23 results